CN106420786A - Pharmaceutical composition for treating gastric ulcer - Google Patents
Pharmaceutical composition for treating gastric ulcer Download PDFInfo
- Publication number
- CN106420786A CN106420786A CN201611209346.8A CN201611209346A CN106420786A CN 106420786 A CN106420786 A CN 106420786A CN 201611209346 A CN201611209346 A CN 201611209346A CN 106420786 A CN106420786 A CN 106420786A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- gastric ulcer
- halcinonide
- rutin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating gastric ulcer, which is prepared from the main raw materials in parts by weight: 20 to 30 parts of kudzuvine root flavone, 5 to 15 parts of atropine sulphate, 8 to 12 parts of halcinonide, 8 to 14 parts of tea polyphenol, 4 to 6 parts of calcium gluconate, 17 to 23 parts of formononetin, 8 to 15 parts of bilobalide C, 2 to 7 parts of schisantherin, and 3 to 9 parts of rutin. The pharmaceutical composition provided by the invention has abilities on diminishing inflammation and recovering stomach so as to achieve the aim of comprehensive rehabilitation, treats both symptoms and root causes, and is short in treatment course, fast in effect, less in toxic and side effects, and low in cost.
Description
Technical field
The present invention relates to a kind of field of medicine preparation, specifically a kind of pharmaceutical composition treating gastric ulcer.
Background technology
Gastropathy is the commonly encountered diseases threatening human health, impact people to work, live, according to statistics every five men or every ten
Just there is a patients with gastric disease in woman, and during morbidity, be often accompanied by stomach distending pain, inappetence, nausea, gastrorrhagia, stomach are worn
Hole, pylorus infraction, even result in canceration, the serious life that have impact on patient, health, work, until threat to life.And this
The sickness rate planting disease is in the trend rising year by year, and therefore, how effectively preventing gastropathy is the mesh that countless medical personnels seek
Mark.And peptic ulcer is most commonly encountered diseases in gastropathy.Digestive tract ulcer (pepticulcer, PU) refers mainly to occur in harmonization of the stomach
Duodenal chronic ulcer, i.e. gastric ulcer and duodenal ulcer, also can betide lower esophageal, gastroduodenal anastomotic stoma
Nearby and Meckel diverticulum.Doctor trained in Western medicine is summarized as limitation tissue defect, can involve the disease of mucosa, Submucosa and muscle layer
Disease, the traditional Chinese medical science is belonged to the category of " gastric abscess " according to its clinical symptoms.This course of disease is longer, recurrent exerbation, clinical manifestation
Complexity, is a kind of global common Chronic gastrointestinal disorders.There is document announcement, peptic ulcer accounts for domestic gastroscopy crowd's
10.3%～2.6%.This disease is found in any age, in the majority with 20～50 years old, and male is more than women (2～5：1), clinically ten
Two Duodenalulcers are more than gastric ulcer, and ratio between two is about 3: 1.Peptic ulcer is caused by many factors it is generally recognized that digestibility
Ulcer is because unbalance between the damage factor of gastric mucosa and defending factors.When the damage factor to gastric mucosa is more than defence
During factor, Peptic Ulcerss may be formed, additionally, the participation of also Nervous and Mental Factors, inherited genetic factorss and some other factor, constitutes
Ulcer pathogenetic complexity mechanism of causing a disease.For the pathogeny of peptic ulcer, in traditional therapeutic process, mainly from
The aspect Comprehensive Treatment such as antacid, antiinflammatory and gastric mucosal protection.Commonly using treatment meanss at present is not replaced with gel aluminum hydroxide, method
The medicines such as fourth, cimetidine are controlling acid；Antiinflammatory is come using medicines such as amoxicillin, gentamycins；And adopt happy electuary of enlightening etc.
Carry out gastric mucosal protection.Because pathogenesiss are complicated different, though above medicine respectively has its favourable one side, eliminate symptom,
Promote healing, reduction relapse rate aspect all undesirable, certain curative effect can be reached using above means, but generally require 1～2
Month time, the course for the treatment of is long, and also needing to of having is hospitalized for observation, and some medicines also need to intravenous administration, have well various in therapeutic process
Points for attention.Therapeutic process bothers, and expense is also higher.Although also having the Chinese medicine of some treatment gastric ulcers, due to effect not
It is fairly obvious, patient is still frequently with western medicine.Common Western medicine be usually be used for pain relieving, Western medicine pain relieving is often
Cause dependency and the drug resistance of medicine, and with certain side effect, the particularly infringement to liver, kidney is especially prominent, takes stopgap measures
Do not effect a permanent cure.In treatment this problem of peptic ulcer, no matter international and domestic, synthetic drug or Chinese patent medicine all suffer from cure rate
The problems such as low, high recurrence rate, so improving the cure rate of peptic ulcer and reducing the key that its relapse rate is problem.Up till now
Till, not yet find a kind of medicine treating gastropathy and the preparation method for the treatment of both the principal and secondary aspects of a disease.
Therefore, it is badly in need of researching and developing a kind of suitable good effect, speed is fast, price is low, the Western medicine compound that has no toxic side effect.
Content of the invention
It is an object of the invention to provide a kind of pharmaceutical composition treating gastric ulcer, to solve to carry in above-mentioned background technology
The problem going out.
For achieving the above object, the present invention provides following technical scheme：
A kind of pharmaceutical composition treating gastric ulcer is it is characterised in that the primary raw material according to weight portion is：Radix Puerariae flavone
20-30 part, atropine sulfate 5-15 part, halcinonide 8-12 part, tea polyphenols 8-14 part, calcium gluconate 4-6 part, Radix Ononis hircinae are yellow
Plain 17-23 part, ginkalide C 8-15 part, schizantherin 2-7 part, rutin 3-9 part.
As the further scheme of the present invention：The pharmaceutical composition of described treatment gastric ulcer, mainly former according to weight portion
Expect be：Radix Puerariae flavone 25-27 part, atropine sulfate 8-13 part, halcinonide 9-11 part, tea polyphenols 10-12 part, calcium gluconate
4-6 part, formononetin 18-21 part, ginkalide C 10-13 part, schizantherin 2-7 part, rutin 3-9 part.
As the further scheme of the present invention：The pharmaceutical composition of described treatment gastric ulcer, mainly former according to weight portion
Expect be：26 parts of Radix Puerariae flavone, 11 parts of atropine sulfate, 10 parts of halcinonide, 11 parts of tea polyphenols, 5 parts of calcium gluconate, Radix Ononis hircinae
20 parts of flavin, 12 parts of ginkalide C, 5 parts of schizantherin, 6 parts of rutin.
A kind of preparation method of the pharmaceutical composition treating gastric ulcer, concretely comprises the following steps：
First, in pharmaceutical grade clean area, Radix Puerariae flavone, atropine sulfate, halcinonide, tea are weighed by above-mentioned metering ratio
Polyphenol, calcium gluconate, formononetin, ginkalide C, schizantherin, rutin, sieve, and machinery adds ultra-pure water after mixing,
Place pharmacy mixer in, mix 4-8min, control RSD≤5%, tabletting cold drying after mixing, temperature control at 15 DEG C,
Packaging obtains final product the pharmaceutical composition for the treatment of gastric ulcer.
As the further scheme of the present invention：6min is mixed in concrete steps.
Compared with prior art, the invention has the beneficial effects as follows：
Medicine of the present invention has antiinflammatory and repairs stomach ability, thus reaching the purpose of comprehensive rehabilitation, treating both the principal and secondary aspects of a disease, the course for the treatment of
Short, instant effect, toxic and side effects are little, and cost is very cheap.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the present invention, rather than whole embodiments.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of not making creative work, all
Belong to the scope of protection of the invention.
Embodiment 1
A kind of pharmaceutical composition treating gastric ulcer is it is characterised in that the primary raw material according to weight portion is：Radix Puerariae flavone
23 parts, 5 parts of atropine sulfate, 8 parts of halcinonide, 8 parts of tea polyphenols, 4 parts of calcium gluconate, 17 parts of formononetin, in Semen Ginkgo
8 parts of ester C, 2 parts of schizantherin, 3 parts of rutin.
A kind of preparation method of the pharmaceutical composition treating gastric ulcer, concretely comprises the following steps：
First, in pharmaceutical grade clean area, Radix Puerariae flavone, atropine sulfate, halcinonide, tea are weighed by above-mentioned metering ratio
Polyphenol, calcium gluconate, formononetin, ginkalide C, schizantherin, rutin, sieve, and machinery adds ultra-pure water after mixing,
Place in pharmacy mixer, mix 4min, control RSD≤5%, tabletting cold drying after mixing, temperature control, at 15 DEG C, is wrapped
Dress obtains final product the pharmaceutical composition for the treatment of gastric ulcer.
Embodiment 2
A kind of pharmaceutical composition treating gastric ulcer is it is characterised in that the primary raw material according to weight portion is：Radix Puerariae flavone
25 parts, 8 parts of atropine sulfate, 9 parts of halcinonide, 10 parts of tea polyphenols, 4 parts of calcium gluconate, 18 parts of formononetin, in Semen Ginkgo
10 parts of ester C, 2 parts of schizantherin, 3 parts of rutin.
A kind of preparation method of the pharmaceutical composition treating gastric ulcer, concretely comprises the following steps：
First, in pharmaceutical grade clean area, Radix Puerariae flavone, atropine sulfate, halcinonide, tea are weighed by above-mentioned metering ratio
Polyphenol, calcium gluconate, formononetin, ginkalide C, schizantherin, rutin, sieve, and machinery adds ultra-pure water after mixing,
Place in pharmacy mixer, mix 4min, control RSD≤5%, tabletting cold drying after mixing, temperature control, at 15 DEG C, is wrapped
Dress obtains final product the pharmaceutical composition for the treatment of gastric ulcer.
Embodiment 3
A kind of pharmaceutical composition treating gastric ulcer is it is characterised in that the primary raw material according to weight portion is：Radix Puerariae flavone
26 parts, 11 parts of atropine sulfate, 10 parts of halcinonide, 11 parts of tea polyphenols, 5 parts of calcium gluconate, 20 parts of formononetin, Semen Ginkgo
12 parts of lactone C, 5 parts of schizantherin, 6 parts of rutin.
A kind of preparation method of the pharmaceutical composition treating gastric ulcer, concretely comprises the following steps：
First, in pharmaceutical grade clean area, Radix Puerariae flavone, atropine sulfate, halcinonide, tea are weighed by above-mentioned metering ratio
Polyphenol, calcium gluconate, formononetin, ginkalide C, schizantherin, rutin, sieve, and machinery adds ultra-pure water after mixing,
Place in pharmacy mixer, mix 6min, control RSD≤5%, tabletting cold drying after mixing, temperature control, at 15 DEG C, is wrapped
Dress obtains final product the pharmaceutical composition for the treatment of gastric ulcer.
Embodiment 4
A kind of pharmaceutical composition treating gastric ulcer is it is characterised in that the primary raw material according to weight portion is：Radix Puerariae flavone
27 parts, 13 parts of atropine sulfate, 11 parts of halcinonide, 12 parts of tea polyphenols, 6 parts of calcium gluconate, 21 parts of formononetin, Semen Ginkgo
13 parts of lactone C, 7 parts of schizantherin, 9 parts of rutin.
A kind of preparation method of the pharmaceutical composition treating gastric ulcer, concretely comprises the following steps：
First, in pharmaceutical grade clean area, Radix Puerariae flavone, atropine sulfate, halcinonide, tea are weighed by above-mentioned metering ratio
Polyphenol, calcium gluconate, formononetin, ginkalide C, schizantherin, rutin, sieve, and machinery adds ultra-pure water after mixing,
Place in pharmacy mixer, mix 8min, control RSD≤5%, tabletting cold drying after mixing, temperature control, at 15 DEG C, is wrapped
Dress obtains final product the pharmaceutical composition for the treatment of gastric ulcer.
Embodiment 5
A kind of pharmaceutical composition treating gastric ulcer is it is characterised in that the primary raw material according to weight portion is：Radix Puerariae flavone
28 parts, 15 parts of atropine sulfate, 12 parts of halcinonide, 14 parts of tea polyphenols, 6 parts of calcium gluconate, 23 parts of formononetin, Semen Ginkgo
15 parts of lactone C, 7 parts of schizantherin, 9 parts of rutin.
A kind of preparation method of the pharmaceutical composition treating gastric ulcer, concretely comprises the following steps：
First, in pharmaceutical grade clean area, Radix Puerariae flavone, atropine sulfate, halcinonide, tea are weighed by above-mentioned metering ratio
Polyphenol, calcium gluconate, formononetin, ginkalide C, schizantherin, rutin, sieve, and machinery adds ultra-pure water after mixing,
Place in pharmacy mixer, mix 8min, control RSD≤5%, tabletting cold drying after mixing, temperature control, at 15 DEG C, is wrapped
Dress obtains final product the pharmaceutical composition for the treatment of gastric ulcer.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of the spirit or essential attributes of the present invention, the present invention can be realized in other specific forms.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit requires rather than described above limits, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although this specification is been described by according to embodiment, not each embodiment only wraps
Containing an independent technical scheme, only for clarity, those skilled in the art should for this narrating mode of description
Using description as an entirety, the technical scheme in each embodiment can also form those skilled in the art through appropriately combined
Understandable other embodiment.
Claims (5)
1. a kind of pharmaceutical composition treating gastric ulcer is it is characterised in that the primary raw material according to weight portion is：Radix Puerariae flavone
20-30 part, atropine sulfate 5-15 part, halcinonide 8-12 part, tea polyphenols 8-14 part, calcium gluconate 4-6 part, Radix Ononis hircinae are yellow
Plain 17-23 part, ginkalide C 8-15 part, schizantherin 2-7 part, rutin 3-9 part.
2. the pharmaceutical composition for the treatment of gastric ulcer according to claim 1 is it is characterised in that the medicine of described treatment gastric ulcer
Compositions, the primary raw material according to weight portion is：Radix Puerariae flavone 25-27 part, atropine sulfate 8-13 part, halcinonide 9-11
Part, tea polyphenols 10-12 part, calcium gluconate 4-6 part, formononetin 18-21 part, ginkalide C 10-13 part, schizantherin
2-7 part, rutin 3-9 part.
3. the pharmaceutical composition for the treatment of gastric ulcer according to claim 1 and 2 is it is characterised in that described treatment gastric ulcer
Pharmaceutical composition, the primary raw material according to weight portion is：26 parts of Radix Puerariae flavone, 11 parts of atropine sulfate, 10 parts of halcinonide,
11 parts of tea polyphenols, 5 parts of calcium gluconate, 20 parts of formononetin, 12 parts of ginkalide C, 5 parts of schizantherin, 6 parts of rutin.
4. a kind of preparation method of the pharmaceutical composition of described treatment gastric ulcer as arbitrary in claim 1-3 it is characterised in that
Concretely comprise the following steps：
First, in pharmaceutical grade clean area, Radix Puerariae flavone, atropine sulfate, halcinonide, tea are weighed by above-mentioned metering ratio many
Phenol, calcium gluconate, formononetin, ginkalide C, schizantherin, rutin, sieve, and machinery adds ultra-pure water after mixing, and puts
Put in pharmacy mixer, mix 4-8min, control RSD≤5%, tabletting cold drying after mixing, temperature control, at 15 DEG C, is wrapped
Dress obtains final product the pharmaceutical composition for the treatment of gastric ulcer.
5. the preparation method of the pharmaceutical composition for the treatment of gastric ulcer according to claim 4 is it is characterised in that concrete steps
Middle mixing 6min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611209346.8A CN106420786A (en) | 2016-12-23 | 2016-12-23 | Pharmaceutical composition for treating gastric ulcer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611209346.8A CN106420786A (en) | 2016-12-23 | 2016-12-23 | Pharmaceutical composition for treating gastric ulcer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106420786A true CN106420786A (en) | 2017-02-22 |
Family
ID=58215966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611209346.8A Withdrawn CN106420786A (en) | 2016-12-23 | 2016-12-23 | Pharmaceutical composition for treating gastric ulcer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106420786A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101926818A (en) * | 2008-12-25 | 2010-12-29 | 天津康鸿医药科技发展有限公司 | Medicine composition containing tea polyphenol and alginic acid and application thereof |
| CN103372191A (en) * | 2012-04-26 | 2013-10-30 | 北京燕康科技有限公司 | Formula with effects of invigorating stomach and protecting liver and production process of formula |
| CN103404665A (en) * | 2013-08-19 | 2013-11-27 | 北京绿源求证科技发展有限责任公司 | Edible health maintenance dissolved medicinal tea capable of protecting gastric mucosa |
| CN104402877A (en) * | 2014-12-07 | 2015-03-11 | 河南豫辰药业股份有限公司 | Preparation method of atropine sulphate |
| CN105693704A (en) * | 2016-01-20 | 2016-06-22 | 南京大学连云港高新技术研究院 | Structure modifier of formononetin |
-
2016
- 2016-12-23 CN CN201611209346.8A patent/CN106420786A/en not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101926818A (en) * | 2008-12-25 | 2010-12-29 | 天津康鸿医药科技发展有限公司 | Medicine composition containing tea polyphenol and alginic acid and application thereof |
| CN103372191A (en) * | 2012-04-26 | 2013-10-30 | 北京燕康科技有限公司 | Formula with effects of invigorating stomach and protecting liver and production process of formula |
| CN103404665A (en) * | 2013-08-19 | 2013-11-27 | 北京绿源求证科技发展有限责任公司 | Edible health maintenance dissolved medicinal tea capable of protecting gastric mucosa |
| CN104402877A (en) * | 2014-12-07 | 2015-03-11 | 河南豫辰药业股份有限公司 | Preparation method of atropine sulphate |
| CN105693704A (en) * | 2016-01-20 | 2016-06-22 | 南京大学连云港高新技术研究院 | Structure modifier of formononetin |
Non-Patent Citations (4)
| Title |
|---|
| 中国科学院: "《中国科学院科技成果汇编》", 31 October 2000 * |
| 李凤龙等编著: "《临床药物手册》", 30 September 1992, 天津：天津科学技术出版社 * |
| 甘友清主编: "《医药商品学》", 30 June 2006, 北京：中国中医药出版社 * |
| 高雁等: "五味子有效成分的药理作用研究进展", 《中医药学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103860591B (en) | A kind of come off for hemorrhoid after the external Miao medicine and preparation method thereof of promoting tissue regeneration and ulcer healing | |
| CN103055260A (en) | Traditional Chinese medicine composition for treating ulcerative colitis and preparation method thereof | |
| CN102210818B (en) | Chinese medicine for treating gastrorrhagia | |
| CN101919969B (en) | Traditional Chinese medicine oral liquid preparation for treating hemorrhoids | |
| CN106420786A (en) | Pharmaceutical composition for treating gastric ulcer | |
| CN103585565A (en) | Anticancer traditional Chinese medicine and preparation method | |
| CN106511505A (en) | Medicine composition for treating gastric ulcer | |
| CN106728145A (en) | It is a kind of to treat Chinese and western medicinal composition of acute diarrhea and preparation method thereof | |
| CN102949660B (en) | Traditional Chinese medicine powder for treating atrophic gastritis and preparation method thereof | |
| CN106581050A (en) | Medicine for treating gastric ulcer | |
| CN106491638A (en) | A kind of medicine for treating superficial gastritiss | |
| CN104042646A (en) | Hemorrhoids cream and preparation method thereof | |
| CN104147110A (en) | Traditional Chinese medicine formula and compound preparation for treating haemorrhoids | |
| CN102028790B (en) | Medicament for treating ulcer of digestive system | |
| CN101185697B (en) | Ointment medicine for treating anal fissure | |
| CN107961358A (en) | A kind of Chinese medicine for treating chronic gastritis and preparation method thereof | |
| CN101856410A (en) | Hemostatic and antiphlogistic medicament and use thereof | |
| CN103919864A (en) | Medicament for treating chronic colitis | |
| CN101987172A (en) | Antidiarrheic Chinese medicine and preparation method thereof | |
| CN105288528A (en) | Medicinal liquor for treating spleen-stomach disharmony | |
| CN102198244B (en) | Medicament for treating gastric and duodenal ulcers, gastritis and other diseases and preparation method thereof | |
| CN104606418A (en) | Traditional Chinese medicinal composition for treating various types of gastritis and indigestion | |
| CN105456305A (en) | Chinese and western mixture compound medicine for treating duodenal ulcers, gastric ulcers, gastric erosion and gastric perforation and preparation method thereof | |
| CN103566144A (en) | Empirical prescription for treating epigastric pain | |
| CN112741865A (en) | Medicine formula for treating esophagus cancer, preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170222 |